Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 60 years;~* Body weight between 45 and 125 kg;~* Documented chronic hepatitis C genotype 1;~* Liver biopsy with histology consistent with chronic hepatitis and no other etiology for chronic liver disease within of 5 years of Day 1;~* Participant and participant's partner(s) must each agree to use acceptable methods of contraception 2 weeks prior to Day 1 and at least 6 months after the last dose of study medication;~* Written informed consent.~Exclusion Criteria:~Include, but are not limited to, the following:~* Prior treatment for hepatitis C;~* Co-infection with HIV or hepatitis B virus (HBsAg positive);~* Evidence of decompensated liver disease;~* Diabetic and hypertensive participants with clinically significant ocular exam findings;~* Pre-existing psychiatric condition, including but not limited to:~  * Current moderate or severe depression;~ * History of depression associated with any of the following:~    * Hospitalization for depression;~   * Electroconvulsive therapy for depression;~   * Depression that resulted in a prolonged absence from work and/or significant disruption of daily functions;~ * Suicidal or homicidal ideation and/or attempt;~ * History of severe psychiatric disorders (including but not limited to schizophrenia, psychosis, bipolar disorder, post-traumatic stress disorder or mania);~ * Past history or current use of lithium;~ * Past history or current use of antipsychotic drugs for listed conditions.~* Substance abuse within protocol specified timeframes;~* Pre-existing medical conditions that could interfere with the participant's participation in and completion of the study, including but not limited to chronic pulmonary disease, cardiac dysfunction or immunologically-mediated disease;~* Active or suspected malignancy or history of malignancy within the past 5 years;~* Participants who are pregnant or nursing; participants who intend to become pregnant during the study period. Male participants with partners who are, or intend to become, pregnant during the study period.~* Treatment with any investigational drug or participation in any clinical trial 30 days within Screening;~* Hemoglobin \<12 g/dL for females and \<13 g/dL for males;~* Neutrophils \<1500 mm\^3; Blacks: \<1200/mm\^3;~* Platelets \<100,000/mm\^3;~* Other clinically significant laboratory test abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1. PEG +RBV for 48 Wks (Part I) (Type: ACTIVE_COMPARATOR): Participants treated with PegIntron (1.5 μg/kg, once weekly \[QW\]) and Ribavirin (800 to 1400 mg/day) for 48 weeks.~Participants with detectable HCV-RNA levels after 24 weeks of treatment had the option of crossing over to receive 24 weeks of PegIntron (1.5 μg/kg, QW), Ribavirin (800 to 1400 mg/day), and boceprevir (800 mg three times daily \[TID\]) for 24 additional weeks. The participants that crossed over to receive boceprevir formed Arm 8. The total treatment duration was up to 54 weeks.
- Arm 2. PEG + RBV + BOC for 28 Wks (Part I) (Type: EXPERIMENTAL): Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.
- Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I) (Type: EXPERIMENTAL): Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.
- Arm 4. PEG +RBV + BOC for 48 Wks (Part I) (Type: EXPERIMENTAL): Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.
- Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I) (Type: EXPERIMENTAL): Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.
- Arm 6. PEG + RBV + BOC for 48 Wks (Part II) (Type: EXPERIMENTAL): Participants receiving PegIntron (1.5 μg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
- Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II) (Type: EXPERIMENTAL): Participants receiving PegIntron (1.5 μg/kg QW), low-dose ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks (Arm 7) during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
- Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I) (Type: EXPERIMENTAL): Participants that started in Arm 1 and had detectable HCV-RNA levels after 24 weeks of treatment had the option of receiving boceprevir (800 mg TID) with~PegIntron (1.5 μg/kg QW), and ribavirin (800 to 1400 mg/day). Participants that took the option of crossing over to receive PegIntron, ribavirin, and boceprevir (800 mg TID) for 24 additional weeks constitute Arm 8. The total treatment duration was up to 54 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).